Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.07

€1.07

2.900%
0.03
2.900%
€4.00

€4.00

 
11:16 / Tradegate WKN: A0LBCR / Name: Sernova / Stock / Healthcare Equipment & Supplies / Micro Cap /
Latest predictions
€4.00
15.01.21
buy
-
01.07.20
buy
Your prediction

Sernova Corp. Stock

There is an upward development for Sernova Corp. compared to yesterday, with an increase of €0.030 (2.900%).
With 0 Sell predictions and 2 Buy predictions the community sentiment towards the Sernova Corp. stock is not clear.
Based on the current price of €1.07 the target price of €4.00 shows a potential of 275.587% for Sernova Corp. which would more than double the current price.

Pros and Cons of Sernova Corp. in the next few years

Pros
?
Market Position
?
Brand
?
Shareholder structure
Cons
?
Growth compared to competition
?
Conscious of the environment
?
Worthwhile Investment for the next years
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Sernova Corp. vs. its peers

Security Change (%) 1w 1m 1y YTD 3y 5y
Sernova Corp. 2.900% -2.817% 21.024% 1093.772% 167.097% - -
Blackstone Ventures - -42.857% 13.208% -58.333% 93.548% 0.000% -85.507%
Aequus Pharmaceuticals Inc -4.320% 4.514% 11.896% 99.602% 135.156% - -
Humanoptics AG 3.880% 0.000% 1.923% -6.195% 27.711% - -

Other discussions about Sernova Corp. Stock

New thread Forum

News

Sernova Announces Presentation at the American Diabetes Association 81st Scientific Sessions

LONDON, ONTARIO – April 6, 2021 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE/XETRA:PSH), a leading clinical-stage regenerative medicine therapeutics company, is pleased to announce that lead

Sernova Provides Positive Outlook Regarding the Development of Its Innovative Therapeutics Platform Technology for Chronic Diseases

Sernova is the first and only regenerative medicine therapeutics platform company to demonstrate a well-vascularized subcutaneous islet transplant technology achieving persistent islet graft

Sernova Announces Closing of C$23 Million Bought Deal Financing Including Full Exercise of Over-Allotment Option

LONDON, ONTARIO – March 1, 2021 – Sernova Corp. (“Sernova” or the “Company”) (TSX-V: SVA) (OTCQB: SEOVF) (Frankfurt/Xetra: PSH), a leading clinical-stage regenerative medicine therapeutics